Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05211232Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing Tislelizumab Arm with Placebo Arm (2 arms). Primary endpoints: Complete Response at 9 weeks and Progression-free Survival at 3 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05211232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211232.